Sector
PharmaceuticalsOpen
₹10,000Prev. Close
₹10,057Turnover(Lac.)
₹6,706.25Day's High
₹10,145Day's Low
₹9,81352 Week's High
₹10,13052 Week's Low
₹6,069.7Book Value
₹331.06Face Value
₹2Mkt Cap (₹ Cr.)
25,136.25P/E
143.83EPS
70.02Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 706.92 | 583.69 | 506.39 | 451.17 |
Net Worth | 711.92 | 588.69 | 511.39 | 456.17 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 805.6 | 813.56 | 831.81 | 571 |
yoy growth (%) | -0.97 | -2.19 | 45.67 | 5.01 |
Raw materials | -311.96 | -294.95 | -305.23 | -181.09 |
As % of sales | 38.72 | 36.25 | 36.69 | 31.71 |
Employee costs | -230.21 | -219.54 | -216.7 | -153.53 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 83.04 | 127.09 | 113.97 | 43.8 |
Depreciation | -16.95 | -20.13 | -18.58 | -14.74 |
Tax paid | -21.44 | -33.79 | -41.76 | -17.89 |
Working capital | 57.86 | 101.15 | 103.65 | 52.76 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -0.97 | -2.19 | 45.67 | 5.01 |
Op profit growth | -36.38 | 12.23 | 160.74 | 25.31 |
EBIT growth | -34.47 | 11.35 | 162.8 | 23.38 |
Net profit growth | -33.97 | 29.2 | 178.69 | 29.22 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,688.8 | 94.92 | 4,06,519.32 | 2,000.46 | 0.94 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,674 | 79.63 | 1,75,903.46 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,510.8 | 24.7 | 1,21,666.43 | 1,485.4 | 1.06 | 4,254.47 | 397.42 |
Dr Reddys Laboratories Ltd DRREDDY | 1,348.8 | 20.58 | 1,10,089.7 | 1,200.7 | 0.61 | 5,546.3 | 345.81 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,221 | 56.47 | 1,07,600.51 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
Narayan K Seshadri
Non-Exec. & Independent Dir.
Revathy Ashok
Non-Exec. & Independent Dir.
Shilpa Divekar Nirula
Managing Director
Sanjeev Panchal
Non Executive Director
Hooi Bien Chuah
Non Executive Director
Sylvia Lorena Varela Ramon
Executive Director
Bhavana Agrawal
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Astrazeneca Pharma India Ltd
Summary
AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company. The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology.AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Companys issued and paid up equity share capital. Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company. AstraZeneca Pharmaceuticals AB Sweden. AstraZeneca Pharma India Limited (the Company) is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC, United Kingdom.The company expanded the installed capacity of Injectables during the year 2001 by 0.20 crores (Nos) and with this expansion the total capacity has been increased to 2.40 crores (Nos).The Companys marketing activities including medical services have been certified for ISO 9002. During 2001-02 the company has
Read More
The Astrazeneca Pharma India Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹10054.5 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Astrazeneca Pharma India Ltd is ₹25136.25 Cr. as of 10 Jun ‘25
The PE and PB ratios of Astrazeneca Pharma India Ltd is 143.83 and 32.68 as of 10 Jun ‘25
The 52-week high/low is the highest and lowest price at which a Astrazeneca Pharma India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Astrazeneca Pharma India Ltd is ₹6069.7 and ₹10130 as of 10 Jun ‘25
Astrazeneca Pharma India Ltd's CAGR for 5 Years at 24.14%, 3 Years at 50.01%, 1 Year at 61.40%, 6 Month at 51.48%, 3 Month at 31.88% and 1 Month at 26.18%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.